招商国证生物医药指数(LOF)C(012417)利润分配表
| |
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
| 收入 |
-2,817,785,436.81 |
-3,439,501,619.59 |
-2,768,919,027.27 |
-3,023,348,760.80 |
| 利息合计 |
2,379,401.34 |
1,964,826.12 |
6,471,967.87 |
3,227,508.49 |
| 其中：存款利息收入 |
845,187.64 |
466,590.17 |
2,441,526.62 |
1,392,239.61 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-1,584,379,860.04 |
-800,225,782.40 |
-1,067,310,848.63 |
-361,788,843.35 |
| 其中：股票投资收益 |
-1,739,242,818.10 |
-908,684,757.26 |
-1,183,064,056.26 |
-447,454,890.39 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
7,083,373.38 |
4,418,986.40 |
1,362,303.38 |
26,047.34 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
147,779,584.68 |
104,039,988.46 |
114,390,904.25 |
85,639,999.70 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-1,242,712,850.55 |
-2,642,928,010.47 |
-1,713,720,436.35 |
-2,668,099,520.46 |
| 其他收入 |
6,927,872.44 |
1,687,347.16 |
5,640,289.84 |
3,312,094.52 |
| 费用 |
125,408,149.72 |
64,313,328.13 |
167,111,326.07 |
85,698,519.00 |
| 管理人报酬 |
101,034,091.08 |
51,849,495.96 |
133,943,706.32 |
68,274,176.26 |
| 基金托管费 |
20,206,818.18 |
10,369,899.17 |
28,217,959.00 |
15,020,318.74 |
| 销售服务费 |
1,869,968.73 |
916,710.64 |
1,981,660.24 |
894,293.83 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
2,291,230.40 |
1,171,621.04 |
2,953,188.90 |
1,503,018.64 |
| 利润总额 |
-2,943,193,586.53 |
-3,503,814,947.72 |
-2,936,030,353.34 |
-3,109,047,279.80 |
微信公众号
证券之星APP
基本资料
